Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Company profile
Ticker
NOTV
Exchange
Website
CEO
Mr. Robert W. Leasure Jr.
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOANALYTICAL SYSTEMS INC
SEC CIK
Corporate docs
Subsidiaries
Inotiv Research • BAS Evansville, Inc. • Seventh Wave Laboratories, LLC • BASi Gaithersburg, LLC • Bronco Research • Histion, LLC • Inotiv Boulder, LLC • Integrated Laboratory Systems, LLC • Inotiv Nashville, LLC • Envigo Global Services, Inc. ...
IRS number
351345024
NOTV stock data
Analyst ratings and price targets
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
16 Oct 24
S-3
Shelf registration
3 Oct 24
8-K
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity
18 Sep 24
8-K
Entry into a Material Definitive Agreement
9 Aug 24
424B5
Prospectus supplement for primary offering
9 Aug 24
10-Q
2024 Q3
Quarterly report
8 Aug 24
8-K
Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update
8 Aug 24
8-K
Entry into a Material Definitive Agreement
3 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 24
Transcripts
NOTV
Earnings call transcript
2024 Q3
8 Aug 24
NOTV
Earnings call transcript
2024 Q1
7 Feb 24
NOTV
Earnings call transcript
2023 Q4
11 Dec 23
NOTV
Earnings call transcript
2023 Q3
10 Aug 23
NOTV
Earnings call transcript
2023 Q3
10 Aug 23
NOTV
Earnings call transcript
2023 Q2
11 May 23
NOTV
Earnings call transcript
2023 Q1
13 Feb 23
NOTV
Earnings call transcript
2022 Q4
10 Jan 23
NOTV
Earnings call transcript
2022 Q3
11 Aug 22
NOTV
Earnings call transcript
2022 Q2
13 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.43 mm | 14.43 mm | 14.43 mm | 14.43 mm | 14.43 mm | 14.43 mm |
Cash burn (monthly) | 6.09 mm | 630.58 k | 10.98 mm | 9.50 mm | 4.94 mm | (no burn) |
Cash used (since last report) | 22.86 mm | 2.37 mm | 41.24 mm | 35.65 mm | 18.53 mm | n/a |
Cash remaining | -8.42 mm | 12.07 mm | -26.81 mm | -21.22 mm | -4.10 mm | n/a |
Runway (months of cash) | -1.4 | 19.1 | -2.4 | -2.2 | -0.8 | n/a |
Institutional ownership, Q2 2024
20.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 58 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 6.72 bn |
Total shares | 5.41 mm |
Total puts | 36.20 k |
Total calls | 73.90 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Jermyn Street Associates | 1.26 mm | $12.44 mm |
Vanguard | 1.05 mm | $1.75 bn |
American Century Companies | 295.59 k | $490.68 mm |
AMP Ameriprise Financial | 268.09 k | $445.03 mm |
Geode Capital Management | 232.86 k | $386.63 mm |
BLK BlackRock | 212.79 k | $353.23 mm |
King Luther Capital Management | 198.60 k | $329.68 mm |
Renaissance Technologies | 164.16 k | $272.51 mm |
Two Sigma Investments | 151.78 k | $251.95 mm |
D. E. Shaw & Co. | 147.88 k | $245.48 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Aug 24 | Harrington Michael J | Common Stock | Grant | Acquire A | No | No | 0 | 27,500 | 0.00 | 27,500 |
10 Aug 24 | Beth Taylor | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 114,792 |
10 Aug 24 | Beth Taylor | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 20,000 | 32.20 k | 20,000 |
10 Aug 24 | Andrea Castetter | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 20,000 |
10 Aug 24 | Andrea Castetter | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 20,000 | 32.20 k | 20,000 |
10 Aug 24 | Jeffrey Brennan Freeman | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 28,817 |
10 Aug 24 | Jeffrey Brennan Freeman | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 20,000 | 32.20 k | 20,000 |
10 Aug 24 | Jeffrey Arthur Krupp | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 31,065 |
10 Aug 24 | Jeffrey Arthur Krupp | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 20,000 | 32.20 k | 20,000 |